Results 51 to 60 of about 5,122,356 (332)

Pharmacokinetics and Tissue Distribution of Enavogliflozin in Mice and Rats

open access: yesPharmaceutics, 2022
This study investigated the pharmacokinetics and tissue distribution of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor that is currently in phase three clinical trials.
Minyeong Pang   +6 more
doaj   +1 more source

Autophagy in cancer and protein conformational disorders

open access: yesFEBS Letters, EarlyView.
Autophagy plays a crucial role in numerous biological processes, including protein and organelle quality control, development, immunity, and metabolism. Hence, dysregulation or mutations in autophagy‐related genes have been implicated in a wide range of human diseases.
Sergio Attanasio
wiley   +1 more source

Pharmacokinetic Interaction Between Oltipraz and Silymarin in Rats

open access: yesJournal of Pharmacy & Pharmaceutical Sciences, 2009
. Purpose: To evaluate the pharmacokinetic interaction between oltipraz and silymarin after intravenous and oral administration of both drugs to male Sprague–Dawley rats.
Min Kyung Kang   +3 more
doaj   +1 more source

Advances in the Application of Electrospun Drug-Loaded Nanofibers in the Treatment of Oral Ulcers

open access: yesBiomolecules, 2022
Oral ulcers affect oral and systemic health and have high prevalence in the population. There are significant individual differences in the etiology and extent of the disease among patients.
Yangqi Zhou   +4 more
doaj   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

open access: yesMolecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker   +14 more
wiley   +1 more source

Effect of Oral Antacid Administration on the Pharmacokinetics of Oral Fluconazole [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 1990
Absorption and elimination of fluconazole after oral administration of a 100-mg capsule were unaffected by concomitant administration of an antacid containing aluminum and magnesium hydroxides.
Maguy Bromet-Petit   +2 more
openaire   +3 more sources

Advances in the pharmaceutical research of curcumin for oral administration

open access: yesOpen Chemistry, 2023
Curcumin is an isolated phytopolyphenol pigment found in the Curcuma longa, commonly known as turmeric, with various pharmacological properties.
Li Cheng   +8 more
doaj   +1 more source

Circulating tumor DNA (ctDNA) trajectories predict survival in trifluridine/tipiracil‐treated metastatic colorectal cancer patients

open access: yesMolecular Oncology, EarlyView.
The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld   +7 more
wiley   +1 more source

Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals

open access: yesPharmaceutics, 2019
Routes of drug administration and the corresponding physicochemical characteristics of a given route play significant roles in therapeutic efficacy and short term/long term biological effects.
B. Homayun, Xueting Lin, Hyo-Jick Choi
semanticscholar   +1 more source

Targeting the MDM2‐MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy